UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

For the month of ~~October~~April 2025

Commission File Number: 001-41115

GENENTA SCIENCE S.P.A.

(Translation of Registrant’s Name into English)

Via Olgettina No. 58

20132 Milan, Italy

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

This report on Form 6-K is incorporated by reference into the registrant’s registration statement on Form F-3 (File No. 333-271901).

~~Genenta~~Other ~~Science S.p.A. Reports Financial Results for the Six Months Ended June 30, 2025~~Events

~~Genenta~~April ~~Science S.p.A. (“Genenta”) is furnishing this report on Form 6-K to provide its unaudited consolidated financial statements as of June 30,~~ 2025, ~~and~~Annual ~~for~~Ordinary ~~the six months ended June 30, 2025, and to provide its Management~~Shareholders’s ~~Discussion and Analysis of Financial Condition and Results of Operations with respect to such financial statements.~~Meeting

~~The~~On ~~unaudited~~April ~~consolidated financial statements as of June 30~~29, 2025, ~~and~~Genenta ~~for~~Science S.p.A. (the ~~six~~“Company”) ~~months~~held ~~ended~~its ~~June~~Annual ~~30,~~Ordinary ~~2025,~~Shareholders’ ~~are~~Meeting ~~attached~~(the ~~to this Form~~“Shareholders’ ~~6-K~~Meeting”) asin ~~Exhibit~~virtual 99meeting format.1. ~~Management’s~~At ~~Discussion~~the ~~and~~Shareholders’ ~~Analysis~~Meeting, ofthe ~~Financial~~Company’s ~~Condition~~shareholders ~~and~~approved ~~Results~~the ~~of Operations is attached to this Form 6-K as Exhibit 99.2.~~following:

EXHIBIT INDEX

	●	The statutory financial statements for the year ended December 31, 2024, audited by Revicom.

	●	The appointment of three directors to the Company’s Board of Directors (the “Board”), effective as of April 29, 2025, of which one individual is a new director. The new member of the Board is Dr. Francesco Galimi. Armon R. Sharei, Ph.D., continued to serve as a member of the Board. Pierluigi Paracchi, the Company’s Chief Executive Officer, continued to serve on the Board as Chairman.

Exhibit		Title
99.1		Unaudited Consolidated Financial Statements as of June 30, 2025, and for the six months ended June 30, 2025.
99.2		Management’s Discussion and Analysis of Financial Condition and Results of Operations.
101		The following materials from Genenta’s Report on Form 6-K for the six months ended June 30, 2025, formatted in Inline XBRL (eXtensible Business Reporting Language): (i) the Consolidated Balance Sheets, (ii) the Consolidated Statements of Operations and Comprehensive Loss, (iii) the Consolidated Statements of Changes in Shareholders’ Equity, (iv) the Consolidated Statements of Cash Flows, and (v) Notes to the Consolidated Financial Statements.

●

Dr. Francesco Galimi is a physician-executive with over 30 years of experience in healthcare R&D, including leadership roles in private and public biotech companies as well as large pharma companies. Most recently, he was the Senior Vice President and Chief Medical Officer of Adicet Bio, Inc. (Nasdaq: ACET), a company focused on allogeneic cell therapy technologies in hemato-oncology and autoimmune disorders. Previously, he served as the Global Program General Manager at Amgen Inc. (Nasdaq: AMGN), where he led a portfolio of oncology programs, from pre-IND to late-stage. Prior to Amgen, Dr. Galimi was the Head of Clinical Development at Onyx Pharmaceuticals Inc. and the Executive Medical Leader at Genomic Institute of the Novartis Research Foundation. Dr. Galimi holds an M.D. from the University of Torino Medical School with a specialty certification in Medical Oncology and a Ph.D. in Oncology from the University of Torino Medical School. He conducted his post-doctoral research, with a focus on gene transfer models in hematology, at the Salk Institute for Biological Studies in La Jolla, California.

	●	The term of office of each of the newly appointed directors is one year and the aggregate annual directors’ compensation is €105,000.

	●	The newly appointed directors met the following day (on April 30, 2025) and appointed Mr. Paracchi as Chief Executive Officer of the Company and allocated €45,000 as annual compensation for Mr. Paracchi and €30,000 as annual compensation for each of Mr. Galimi and Mr. Sharei.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	GENENTA SCIENCE S.P.A.
Date: October 10, 2025	By:	/s/ Richard B. Slansky
Date: October 27, 2025	By:	/s/ Pierluigi Paracchi
		Richard B. Slansky, Chief Financial Officer
		Pierluigi Paracchi, Chief Executive Officer

Filing Compare · Genenta Science S.p.A.